Homepage
Neurizon are focused on advancing groundbreaking science to reach a new horizon in neurodegenerative disease treatments.

Neurizon Therapeutics advances treatments for people living with neurodegenerative diseases, initially focused on ALS.
neurizon.comCrawled Nov 16, 2026
Neurizon are focused on advancing groundbreaking science to reach a new horizon in neurodegenerative disease treatments.
Neurizon Therapeutics names Dr. Chris Bremer as its new Chief Executive Officer, effective October 1, 2026. Bremer holds advanced degrees in medicine, pharmacy, and business administration. The late-stage biotech company focuses on developing treatments for neurodegenerative diseases.
Neurizon secures a long-term supply agreement with Elanco for human-use monepantel, a compound for its lead neurodegenerative disease candidate NUZ-001 targeting ALS. The deal ensures Neurizon’s pipeline drug has a stable source of the key active ingredient from Elanco’s existing production. Both companies specialize in repurposing animal health compounds for human therapeutic use.
Neurizon Therapeutics expands the **NUZ-001 arm** of the **HEALEY ALS Platform Trial** due to faster-than-expected patient recruitment. The Australian biotech company is now scaling up enrollment for its ALS (amyotrophic lateral sclerosis) therapy candidate in the multi-disease clinical study. The trial leverages the HEALEY ALS Platform, a collaborative initiative designed to accelerate ALS drug development.
The FDA removes its clinical hold on **NUZ-001**, an investigational drug for ALS developed by **Neurizon Therapeutics**. The decision allows the trial to resume after prior regulatory scrutiny. NUZ-001 targets neuroprotective pathways in amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.
Neurizon Therapeutics Limited (formerly PharmAust) rebrands to reflect its focus on neurodegenerative disease treatments. The company operates as a clinical-stage biotech firm and secured shareholder approval for the name change at its October 9, 2024 Annual General Meeting. The updated name, Neurizon Therapeutics, aligns with its specialized therapeutic mission.